|
Anemia, Sickle Cell
|
|
0.010 |
GeneticVariation
|
BEFREE |
Ala-9Val polymorphism of Mn-SOD gene in sickle cell anemia.
|
21574139 |
2011 |
|
Schizophrenia
|
|
0.090 |
GeneticVariation
|
BEFREE |
Additive effect between quinine oxidoreductase gene (NQO1: Pro187Ser) and manganese superoxide dismutase gene (MnSOD: Ala-9Val) polymorphisms on tardive dyskinesia in patients with schizophrenia.
|
18977034 |
2008 |
|
Malignant neoplasm of breast
|
|
0.050 |
GeneticVariation
|
BEFREE |
An alanine-9valine (Ala-9Val) polymorphism in the mitochondrial targeting sequence of MnSOD has been described and has recently been associated with risk of human breast cancer.
|
15386537 |
2005 |
|
Breast Carcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
An alanine-9valine (Ala-9Val) polymorphism in the mitochondrial targeting sequence of MnSOD has been described and has recently been associated with risk of human breast cancer.
|
15386537 |
2005 |
|
Mood Disorders
|
|
0.020 |
GeneticVariation
|
BEFREE |
Analysis of manganese superoxide dismutase (MnSOD: Ala-9Val) and glutathione peroxidase (GSH-Px: Pro 197 Leu) gene polymorphisms in mood disorders.
|
23725507 |
2013 |
|
Recurrent depressive disorder
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis of two polymorphisms of the manganese superoxide dismutase gene (Ile-58Thr and Ala-9Val) in patients with recurrent depressive disorder.
|
20478627 |
2010 |
|
Schizophrenia
|
|
0.090 |
GeneticVariation
|
BEFREE |
Association between Ala-9Val polymorphism of Mn-SOD gene and schizophrenia.
|
15610954 |
2005 |
|
Aggressive periodontitis, generalized
|
|
0.010 |
GeneticVariation
|
BEFREE |
Association between Manganese Superoxide Dismutase (MnSOD Val-9Ala) genotypes with the risk of generalized aggressive periodontitis disease.
|
26718428 |
2015 |
|
Dyskinetic syndrome
|
|
0.020 |
GeneticVariation
|
BEFREE |
Chinese Han patients with schizophrenia were assessed for abnormal involuntary movements, and subgroups of 42 patients with persistent tardive dyskinesia and 59 consistently without dyskinesias were assessed for the DRD3 ser9gly and the MnSOD ala-9val polymorphisms.
|
12960753 |
2003 |
|
Malignant neoplasm of prostate
|
|
0.020 |
GeneticVariation
|
BEFREE |
Effects of manganase superoxide dismutase Ala-9Val polymorphism on prostate cancer: a case-control study.
|
17465268 |
2007 |
|
Prostate carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Effects of manganase superoxide dismutase Ala-9Val polymorphism on prostate cancer: a case-control study.
|
17465268 |
2007 |
|
Sepsis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Evaluating the subgroup of 293 ICU patients with sepsis, a pooled analysis including two genetic variants GPx1 and SOD2 (47C>T SNP, rs4880; protein variant in MnSOD: Ala-9Val) showed a significant difference in relation to progression to septic shock.
|
25497738 |
2015 |
|
Septicemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Evaluating the subgroup of 293 ICU patients with sepsis, a pooled analysis including two genetic variants GPx1 and SOD2 (47C>T SNP, rs4880; protein variant in MnSOD: Ala-9Val) showed a significant difference in relation to progression to septic shock.
|
25497738 |
2015 |
|
Essential Hypertension
|
|
0.010 |
GeneticVariation
|
BEFREE |
Evidence for an association between haptoglobin and MnSOD (Val9Ala) gene polymorphisms in essential hypertension based on a Brazilian case-control study.
|
21053180 |
2010 |
|
Tardive Dyskinesia
|
|
0.090 |
GeneticVariation
|
BEFREE |
Evidence from pooled data for genetic association with tardive dyskinesia (TD) showed (1) in COMT(val158met), using Val-Val homozygotes as reference category, a protective effect for Val-Met heterozygotes (OR=0.63, 95% CI: 0.46-0.86, P=0.004) and Met carriers (OR=0.66, 95% CI: 0.49-0.88, P=0.005); (2) in Taq1A in DRD2, using the A1 variant as reference category, a risk-increasing effect for the A2 variant (OR=1.30, 95% CI: 1.03-1.65, P=0.026), and A2-A2 homozygotes using A1-A1 as reference category (OR=1.80, 95% CI: 1.03-3.15, P=0.037); (3) in MnSOD Ala-9Val, using Ala-Ala homozygotes as reference category, a protective effect for Ala-Val (OR=0.37, 95% CI: 0.17-0.79, P=0.009) and for Val carriers (OR=0.49, 95% CI: 0.24-1.00, P=0.047).
|
18180754 |
2008 |
|
Drug-induced tardive dyskinesia
|
|
0.090 |
GeneticVariation
|
BEFREE |
Evidence from pooled data for genetic association with tardive dyskinesia (TD) showed (1) in COMT(val158met), using Val-Val homozygotes as reference category, a protective effect for Val-Met heterozygotes (OR=0.63, 95% CI: 0.46-0.86, P=0.004) and Met carriers (OR=0.66, 95% CI: 0.49-0.88, P=0.005); (2) in Taq1A in DRD2, using the A1 variant as reference category, a risk-increasing effect for the A2 variant (OR=1.30, 95% CI: 1.03-1.65, P=0.026), and A2-A2 homozygotes using A1-A1 as reference category (OR=1.80, 95% CI: 1.03-3.15, P=0.037); (3) in MnSOD Ala-9Val, using Ala-Ala homozygotes as reference category, a protective effect for Ala-Val (OR=0.37, 95% CI: 0.17-0.79, P=0.009) and for Val carriers (OR=0.49, 95% CI: 0.24-1.00, P=0.047).
|
18180754 |
2008 |
|
Dyskinetic syndrome
|
|
0.020 |
GeneticVariation
|
BEFREE |
Furthermore, we find evidence for an association between Ala-9Val (MnSOD) and TDof, but not TDlt.
|
20041472 |
2010 |
|
Cervix carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Genotypic association of both Val-9Ala and Ile58Thr polymorphisms with cervical cancer and breast cancer of these patients comparing to healthy women was not statistically significant (p<0.05).
|
23886214 |
2013 |
|
Malignant tumor of cervix
|
|
0.010 |
GeneticVariation
|
BEFREE |
Genotypic association of both Val-9Ala and Ile58Thr polymorphisms with cervical cancer and breast cancer of these patients comparing to healthy women was not statistically significant (p<0.05).
|
23886214 |
2013 |
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Genotypic association of both Val-9Ala and Ile58Thr polymorphisms with cervical cancer and breast cancer of these patients comparing to healthy women was not statistically significant (p<0.05).
|
23886214 |
2013 |
|
Breast Carcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
Genotypic association of both Val-9Ala and Ile58Thr polymorphisms with cervical cancer and breast cancer of these patients comparing to healthy women was not statistically significant (p<0.05).
|
23886214 |
2013 |
|
Malignant neoplasm of breast
|
|
0.050 |
GeneticVariation
|
BEFREE |
Genotypic association of both Val-9Ala and Ile58Thr polymorphisms with cervical cancer and breast cancer of these patients comparing to healthy women was not statistically significant (p<0.05).
|
23886214 |
2013 |
|
Parkinson Disease
|
|
0.020 |
GeneticVariation
|
BEFREE |
In addition, both alleles of the Ala9Val polymorphism in the MTS of MnSOD were equally distributed between German PD patients and controls excluding this gene variant as a risk factor for PD in Caucasian subjects.
|
10049782 |
1999 |
|
Chronic Kidney Diseases
|
|
0.010 |
GeneticVariation
|
BEFREE |
In south Indian (SI) subjects there was significant allelic and genotypic association of the wild-type allele in SOD2 (Ala9Val; P=.002 and P=.013, respectively), UCP1 (-112 T>G, P=.012 and P=.009; Ala64Thr, P=.015 and P=.004), NOS3 (Glu298Asp, P=.002 and P=.009) and GSTP1 (Ile105Val, P=.003 and P=.004) genes with development of CRI.
|
18413200 |
2009 |
|
Chronic Kidney Insufficiency
|
|
0.010 |
GeneticVariation
|
BEFREE |
In south Indian (SI) subjects there was significant allelic and genotypic association of the wild-type allele in SOD2 (Ala9Val; P=.002 and P=.013, respectively), UCP1 (-112 T>G, P=.012 and P=.009; Ala64Thr, P=.015 and P=.004), NOS3 (Glu298Asp, P=.002 and P=.009) and GSTP1 (Ile105Val, P=.003 and P=.004) genes with development of CRI.
|
18413200 |
2009 |